BRIEF published on 05/15/2024 at 08:05, 1 year 6 months ago MBB SE Records Significant Earnings Growth in Q1 2024 Financial Performance Dividend Increase MBB SE Quarterly Results EBITDA Growth
PRESS RELEASE published on 05/15/2024 at 08:00, 1 year 6 months ago MBB SE increases EBITDA by 64% to €23 million in the first quarter and achieves 11% EBITDA margin MBB SE increases EBITDA by 64% to €23 million in the first quarter, achieving an 11% EBITDA margin. Company reports revenue growth and dividend proposal EBITDA Revenue Growth Financial Performance Dividend Proposal MBB SE
BRIEF published on 03/26/2024 at 08:19, 1 year 8 months ago MBB SE Targets One Billion Euros in Revenue for 2024 with Strong Growth Ambitions Growth Strategy Financial Performance Dividend Increase MBB SE Revenue Targets
PRESS RELEASE published on 03/26/2024 at 08:14, 1 year 8 months ago MBB SE expects one billion euros in revenue with an EBITDA margin of 10% in 2024 MBB SE expects one billion euros in revenue with an EBITDA margin of 10% in 2024. The Group's diversified segments show varying performance in the 2023 financial year Financial Performance 2024 Outlook Revenue Forecast EBITDA Margin MBB SE
BRIEF published on 03/07/2024 at 17:05, 1 year 8 months ago MBB SE Completes Share Buyback, Acquiring 6.9% of Its Share Capital Growth Strategy Shareholder Value Share Buyback MBB SE Financial Resources
PRESS RELEASE published on 03/07/2024 at 17:00, 1 year 8 months ago MBB SE announces buyback of 393,522 shares or 6.9% of the share capital MBB SE announces buyback of 393,522 shares, equivalent to 6.9% of share capital. Repurchase at €96.00 per share, totaling €37.8 million, to enhance shareholder value and facilitate growth Share Capital Share Buyback MBB SE Value Per Share 393,522 Shares
PRESS RELEASE published on 02/29/2024 at 08:30, 1 year 9 months ago Acceptance period for the share buyback offer of MBB SE at €96.00 per share ends on 4 March 2024 MBB SE's share buyback offer at €96.00 per share ends on 4 March 2024. Shareholders have until the deadline to accept the offer. Details on www.mbb.com/en/ir/shares/buyback Shareholders Share Buyback MBB SE Offer Deadline
BRIEF published on 02/29/2024 at 08:30, 1 year 9 months ago MBB SE announces the end of the acceptance period for its share buyback offer at €96 per share Share Buyback 2024 Financial Market MBB SE Public Offer
PRESS RELEASE published on 01/31/2024 at 18:31, 1 year 10 months ago EQS-Adhoc: MBB resolves public share buyback offer at a price of € 96.00 per share MBB SE announces public share buyback offer at €96.00 per share, aiming to increase value per share and maintain financial resources for growth Share Buyback MBB SE Buyback Offer Value Per Share Financial Resources
PRESS RELEASE published on 11/01/2023 at 09:27, 2 years 1 month ago MBB subsidiary Aumann acquires LACOM, a leading laminating and coating specialist with a focus on battery and fuel cell technology
Published on 12/05/2025 at 02:35, 5 hours 24 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 59 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 54 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 59 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 59 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 4 hours 29 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 8 hours 9 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours 34 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 44 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:00, 13 hours 59 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 14 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 15 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago Declaration of voting rights at the end of November 2025
